Navigation Links
Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients
Date:8/1/2009

SAN FRANCISCO (August 1, 2009)Previously untreated non-small cell lung cancer (NSCLC) patients over the age of 70 respond well to a combination of bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.

"Based on our initial data, the combination appears to be well tolerated and efficacious, though we'll have to wait and see the final results," says Hossein Borghaei, D.O., medical oncologist at Fox Chase, who led the trial.

Elderly patients are often excluded from clinical trials because researchers fear they will have trouble tolerating standard chemotherapy regimens. That leaves open the question of how best to treat these individuals who account for more than half of all NSCLC in the United States.

With that challenge in mind, Borghaei and colleagues designed a trial testing a combination of two molecularly targeted agents in patients 70 years or older. The team reasoned that a combination lacking standard cytotoxic agents may be better tolerated by these patients, potentially without comprising efficacy. "We looked for a regimen that had few side effects, would involve only targeted agents, and had a bit of a track record. This combination was a natural fit," Borghaei says. Several small phase II trials in younger NSCLC patients demonstrated that the combination had anti-tumor activity and a relatively favorable toxicity profile.

Thus far 21 elderly NSCLC patients have enrolled in the Fox Chase trial and 14 are evaluable for response. The median age of the 14 evaluable patients is 78, with a range of 71 to 84 years. Four patients have had partial responses with demonstrable tumor shrinkage and three patients had stable disease by RECIST criteria.

The combination appears safe and well tolerated in this patient population with the most commonly encountered toxicities of clinical relevance being high blood pressure, fatigue, loss of appetite and diarrhea.

"The observed activity of this regimen in this patient population suggests promise and therefore warrants continued investigation," Borghaei says. He also emphasizes that designing a clinical trial just for elderly patients is a novel approach, but one that should be used more in the future given the large proportion of NSCLC patients in this demographic group.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
2. Northstar Healthcare Announces Option to Purchase a 60% Interest in The Palladium for Surgery - Dallas
3. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
4. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
5. Kensey Nash Announces $25 Million Stock Repurchase Program
6. Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance
7. Flextronics Announces Redemption and Change of Control Repurchase Offer for Solectron 8.00% Senior Subordinated Notes and Planned Change of Control Repurchase Offer for Solectrons 0.50% Senior Convertible Notes
8. First Nationwide Class Action Filed on Behalf of Consumers Who Purchased Topps E. Coli Contaminated Ground Beef
9. Hospital Corporation of America Purchases Seventh CyberKnife(R) System
10. Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics
11. Governor Schwarzeneggers Mandatory Purchase of Private Health Insurance Doesnt Add Up for the Middle-Class, Says FTCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , ... May 04, 2016 , ... ... Dr. Todd Rider's research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have ... campaign that starts on May 3, 2016 at http://igg.me/at/EndTheVirus and runs ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... and Continence Nurses (WOCN) Society™ and Canadian Association for Enterostomal Therapy (CAET) ... promotion, time saving and planning tools to attendees and exhibitors for the 2016 ...
(Date:5/4/2016)... ... May 04, 2016 , ... May kicked off with ... across the United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as well ... and focus on skin safety and health now and in the future. , The ...
(Date:5/4/2016)... ... May 04, 2016 , ... Recognizing that lifestyle medicine is essential ... Verywell, have tapped David Katz, MD, MPH, president of the American College of ... to lifestyle medicine is especially gratifying,” said Katz. “There is so much opportunity to ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and NSR-9844XL ... (average retail starting at $59.95) uses 2 included CR-123 batteries to produce up ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... BROOMALL, Pa. , May 3, 2016 ... Attorney Jack Whelan and Delaware County ... NARCAN® (naloxone HCI) Nasal Spray in all ACME ... the U.S. Centers for Disease Control and Prevention (CDC), naloxone has ... 2014, when police officers in Delaware County ...
(Date:5/3/2016)... (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign to ... personal story and encourage those at risk to get tested and begin the road to ... ... ... (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... , May 3, 2016 Intec ... a clinical-stage biopharmaceutical company, today announced the appointment of ... Regulatory Affairs. "Ms. Strauss-Levy has 15 years ... has established an outstanding track record, having supported the ... regulatory approval processes in the United States ...
Breaking Medicine Technology: